Sequential CD19 and BCMA ‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
This study aims to investigate the safety and efficacy of sequential infusion of CD19‐CART and B‐cell maturation antigen (BCMA)‐CARTs for RRMM with a similar 3 + 3 dose escalation combined with a toxicity sentinel design. We enrolled 10 patien ts, among whom 7 received autologous infusion and 3 received allogeneic infusion. The median follow‐up time was 20 months. The most common grade 3/4 treatment‐emergent toxicities were hematological toxicities. Cytokine‐release syndrome (CRS) adverse reactions were grade 1/2 in 9 out of 10 sub jects. No dose‐limited toxicity (DLT) was observed for BCMA‐CAR‐positive T cells ≤5 × 107/kg), while two patients with dose ‐levels of 5–6.5 × 107/kg experienced DLTs. The overall response rate was 90% (five partial responses and four stringent complete responses). Three out of four patients with stringent complete responses to autologous CART had progression ‐free survival for over 2 years. The three patients with allogeneic CART experienced disease progression within 2 months. These results evidence the sequential infusion's preliminarily tolerability and efficacy in RRMM, and present a simple and safe design applicable for the establishment of mul tiple CART therapy.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Lingzhi Yan,
Su Qu,
Jingjing Shang,
Xiaolan Shi,
Liqing Kang,
Nan Xu,
Mingqing Zhu,
Jin Zhou,
Song Jin,
Weiqin Yao,
Ying Yao,
Guanghua Chen,
Huirong Chang,
Xiaming Zhu,
Lei Yu,
Depei Wu,
Chengcheng Fu Tags: ORIGINAL RESEARCH Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Hematology | Myeloma | Neurology | Study | Toxicology